Health Technology Assessment

The internationally acclaimed journal series of the NIHR HTA Programme

HTa journal

Editor-in-Chief:
Professor Tom Walley CBE
View the HTA Editorial Board

Print ISSN: 1366-5278
Online ISSN: 2046-4924
DVD ISSN: 2046-4932
Frequency: 50 per year
Current Volume: 17 / 2013
Impact Factor: 4.255
© 2013 Crown Copyright

Recently published issues | see all

Current issues: Volume 17 Number 18 (May 2013)
Volume 17 Number 17 (April 2013)
Volume 17 Number 16 (April 2013)
Volume 17 Number 15 (April 2013
Volume 17 Number 14 (April 2013)
Volume 17 Number 13 (April 2013)


About Health Technology Assessment journal series

Health Technology Assessment is the peer reviewed journal for the HTA Programme. Reports are published in the HTA journal series if (1) they have resulted from work for the HTA Programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

The journal is indexed on MEDLINE, CINAHL, EMBASE, the Cochrane Library and the ISI Science Citation Index and assessed for inclusion in the Database of Abstracts of Reviews of Effectiveness.

Published journals are available for free download from the website and includes the full text and any appendices, as well as executive summaries (four to six pages) and abstracts or mini-summaries where available (one page). Printed copies are also available at a cost of £20, read more.

View the Supplements

Most popular journals

  • The RATPAC (Randomised Assessment of Treatment using Panel Assay of Cardiac markers) trial: a randomised controlled trial of point-of-care cardiac markers in the emergency department, Health Technol Assess 2011; 15:23
  • Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation, Health Technol Assess 2010; 14:36
  • The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation, Health Technol Assess 2009; 13:41
  • Breastfeeding promotion for infants in neonatal units: a systematic review and economic analysis Health Technol Assess 2009; 13:40
  • Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation, Health Technol Assess 2009; 15:14

Advanced search How to use the search function